|Bid||5.78 x 3000|
|Ask||5.86 x 800|
|Day's range||5.63 - 5.92|
|52-week range||1.43 - 7.80|
|Beta (5Y monthly)||0.87|
|PE ratio (TTM)||N/A|
|Earnings date||10 Nov 2022 - 14 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||10.41|
A big revenue beat couldn't make up for a modest bottom-line miss on Tuesday for CTI BioPharma (NASDAQ: CTIC). This is CTI's drug that was approved by the Food and Drug Administration (FDA) in March for the treatment of myelofibrosis, a rare bone marrow disorder.
CTI BioPharma (CTIC) delivered earnings and revenue surprises of -5% and 20.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
The stock of CTI BioPharma (NASDAQ: CTIC) was an outlier in the biotech sector on Thursday, and in the best way possible. The company's shares surged more than 18% higher on the day, following a new and bullish analyst note on the company based on positive anecdotal evidence. Peaker rates it an unequivocal outperform (read: buy), at a price target of $10 per share.